Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer-Reference-Cited by-同舟云学术

Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer

Published:2020-01 Issue: Volume:12 Page:175883592097813
ISSN:1758-8359
Container-title:Therapeutic Advances in Medical Oncology
language:en
Short-container-title:Ther Adv Med Oncol

Author:

Lavaud Pernelle¹,Dumont Clément²,Thibault Constance³,Albiges Laurence¹,Baciarello Giulia¹,Colomba Emeline¹,Flippot Ronan¹,Fuerea Alina¹,Loriot Yohann¹⁴,Fizazi Karim⁵

Affiliation:

1. Department of Cancer Medicine, Gustave Roussy Cancer Campus, University of Paris Saclay, Villejuif, France

2. Department of Cancer Medicine, Hôpital Saint Louis, Paris, France

3. Department of Medical Oncology, Hôpital Européen Georges-Pompidou, Paris, France

4. INSERM U981, Gustave Roussy Cancer Campus, University of Paris-Sud, University of Paris Saclay, Villejuif, France

5. Department of Cancer Medicine, University of Paris Saclay, Gustave Roussy, 114 Rue Edouard Vaillant, Villejuif, 94805, France

Abstract

Until recently, continuing androgen deprivation therapy (ADT) and closely monitoring patients until evolution towards metastatic castration-resistant prostate cancer (CRPC) were recommended in men with non-metastatic CRPC (nmCRPC). Because delaying the development of metastases and symptoms in these patients is a major issue, several trials have investigated next-generation androgen receptor (AR) axis inhibitors such as apalutamide, darolutamide, and enzalutamide in this setting. This review summarizes the recent advances in the management of nmCRPC, highlighting the favourable impact of next-generation AR inhibitors on metastases-free survival, overall survival and other clinically meaningful endpoints.

Publisher

SAGE Publications

Subject

Oncology

Link

http://journals.sagepub.com/doi/pdf/10.1177/1758835920978134

Reference48 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates

3. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018

4. Comparison of prostate cancer survival in Germany and the USA: can differences be attributed to differences in stage distributions?

5. Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploiting the DNA Damage Response for Prostate Cancer Therapy;Cancers;2023-12-23

2. Making the Case for Autophagy Inhibition as a Therapeutic Strategy in Combination with Androgen-Targeted Therapies in Prostate Cancer;Cancers;2023-10-18

3. The Effect of Gene Editing by CRISPR-Cas9 of miR-21 and the Indirect Target MMP9 in Metastatic Prostate Cancer;International Journal of Molecular Sciences;2023-10-03

4. The crosstalk between ubiquitination and endocrine therapy;Journal of Molecular Medicine;2023-03-24

5. Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial;European Urology;2023-03